Optimising surveillance for relapse of Wilms' tumour
Menée à partir de données portant sur 4 271 patients pédiatriques atteints d'une tumeur de Wilms (durée médiane de suivi : 62 mois), cette étude internationale identifie les méthodes utilisées pour détecter une récidive et estime le nombre d'examens radiologiques subis avant détection d'une récidive subclinique
Wilms' tumour is the most common kidney cancer in children worldwide and, in developed countries, overall survival exceeds 90% at 5 years.1 Although only a minority (around 15%) of patients with Wilms' tumour relapse, salvage therapy for these children is challenging, requiring highly intensive treatments that are only effective for approximately half of patients.2,3 Survivors of relapse can have lifelong health problems and are at risk of secondary malignant neoplasms from toxic therapeutic regimens, which mandate improved therapy with cell-specific activity and fewer off-target sequelae.
The Lancet Oncology , commentaire, 2017